We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Alliance to Recover Leukocytes for Therapeutic Use

By HospiMedica staff writers
Posted on 15 Feb 2001
An alliance to recover leukocytes has been entered into by Pall Corp. More...
(East Hills, NY, USA) and Viragen, Inc. (Plantation, FL, USA). Pall will grant an exclusive (except for Japan) worldwide license to proprietary technology that will enable Viragen to efficiently remove and recover leukocytes from leukoreduction filters. The goal is to provide additional sources of leukocytes for Viragen's production of interferons for therapeutic use.

Viragen's lead product, Omniferon, a multisubtype alpha interferon, is currently in phase II clinical trials for the treatment of hepatitis C. Omniferon is derived from white blood cells using Viragen's unique manufacturing technology. Viragen has white blood cell sourcing agreements with other blood organizations, including the American Red Cross and the German Red Cross.

"Blood centers normally discard blood filters after each use,” noted Gerald Smith, chairman and CEO of Viragen. "The potential access to all filtered white blood cells increases Viragen's capability to maximize production of Omniferon.”

Pall is a leader in the filtrations and separations industry, supplying products for use in transfusion medicine, biopharmaceuticals, and in other industries. Pall blood filters are used in all 10 countries that have mandated universal leukocyte reduction.



Related Links:
Pall
Viragen

Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Patient Monitoring System
AlarmSense
Patient Preoperative Skin Preparation
BD ChloraPrep
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Medical Imaging

view channel
Images from patient T1, who had menstrual cycle–dependent right shoulder pain. (A) Maximum-intensity-projection images show abnormal findings for right diaphragm (arrowhead), bilateral round ligaments, peritoneum around bilateral ovaries, and left fallopian tube. Combined PET/MRI show hyperintense lesion with focal uptake inferior of right diaphragm, indicative of endometriosis (arrowhead, B). Confirmatory laparoscopy demonstrated extensive pelvic disease and implants of right diaphragm (C) that stained intensely positive for FAP (D).  (Image Credit: Schindler P, Brandt J, Bobe S, et al. Initial results of FAPI PET/MRI to assess the extent of endometriosis. J Nucl Med. 2026;67(8):1232–1238. doi:10.2967/jnumed.125.271376)

Targeted PET/MRI Improves Detection and Preoperative Mapping of Endometriosis

Endometriosis is a chronic inflammatory condition in which endometrial-like tissue grows outside the uterus, causing pelvic pain, infertility, and reduced quality of life. Conventional imaging can underestimate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.